Big Pharma Split Corp.：高管交易动态
Big Pharma Split Corp.属于银行行业。其高管的申报经由SEDI发布。过去一年很平静：Big Pharma Split Corp.没有一份高管申报。上一份申报发布于2024年1月19日。
从2018年起的全部记录中，共有2笔买入和1笔卖出。
数据来源：高管申报（SEDI）。过往交易不代表未来收益。
财务数据
财年 2025财年截至 2025年12月 · cache
- 100 股股票TSXSEDI:4245718
- 100 股股票TSXSEDI:4245717
- 1,600 股股票TSXSEDI:4245488
- 1,600 股股票TSXSEDI:4245489
- 2,000 股股票TSXSEDI:4197748
- 2,000 股股票TSXSEDI:4197773
- 2,000 股股票TSXSEDI:4197772
- 200 股股票TSXSEDI:4196941
- 200 股股票TSXSEDI:4196942
- 900 股股票TSXSEDI:4196658
- 900 股股票TSXSEDI:4196659
- 400 股股票TSXSEDI:4193385
- 400 股股票TSXSEDI:4193383
- 400 股股票TSXSEDI:4190180
- 400 股股票TSXSEDI:4190179
- 11,000 股股票TSXSEDI:4187244
- 11,000 股股票TSXSEDI:4187241
- 7,500 股股票TSXSEDI:4183276
- 7,500 股股票TSXSEDI:4183275
- 400 股股票TSXSEDI:4181320
- 400 股股票TSXSEDI:4181323
- 500 股股票TSXSEDI:4178917
- 500 股股票TSXSEDI:4178915
- 1,000 股股票TSXSEDI:4175357
- 1,000 股股票TSXSEDI:4175358
97 条申报中的 25 条
About Big Pharma Split Corp.
In the Big Pharma Split Corp. record, 74 of the 78 filings are lodged by the issuer itself, filed as Issuer, with no purchase or sale. The record has 75 filings of a kind other than purchase or sale, and 62 filings in 2023, against 5 in 2018, 3 in 2019, 2 in 2020, 2 in 2021 and 4 in 2024. The open-market trades are the work of a single director and officer, Michael Kovacs, who has 4 filings: 2 purchases, EUR 9,385 on January 26, 2018 and EUR 4,494 on August 17, 2018, or EUR 13,879 in total, and 1 sale of EUR 12,228 on October 7, 2019. Purchases are 67% of open-market trades. Transactions run from September 25, 2017 to January 18, 2024, published a median of 3 days after the trade. Listed on the Toronto stock exchange, the company has a market capitalisation of CAD 19.1 million and no longer has a filing in the last twelve months. Only 2 filers appear: the issuer and Michael Kovacs.
